Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.68 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.60 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.60 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.60 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.58 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.47 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.47 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.47 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2S,4R-4-Methylglutamate SCHEMBL1060785 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1ENPEP | |
| 2S,4R-4-Methylglutamate SCHEMBL30990075 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1ENPEP | |
| 2S,4R-4-Methylglutamate SCHEMBL2263577 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1ENPEP | |
| 2S,4R-4-Methylglutamate SCHEMBL594187 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1ENPEP | |
| 2S,4R-4-Methylglutamate SCHEMBL7778018 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1ENPEP | |
| 2S,4R-4-Methylglutamate SCHEMBL12497563 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1ENPEP | |
| 2S,4R-4-Methylglutamate SCHEMBL250314 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1ENPEP | |
| 2S,4R-4-Methylglutamate SCHEMBL1133372 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1ENPEP | |
| 2S,4R-4-Methylglutamate SCHEMBL21682833 | 1.00 | SLC7A5 (0.68) | SLC7A5SLC1A3SLC1A2SLC1A1ENPEP | |
| 2S,4R-4-Methylglutamate SCHEMBL8993381 | 0.97 | SLC7A5 (0.65) | SLC7A5SLC1A3SLC1A2SLC1A1ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0809624-B1 | ALKYLCARBOXY AMINO ACIDS-MODULATORS OF THE KAINATE RECEPTOR | BEARSDEN BIO INC (US) | 2001-08-29 | — | — | EP | claimed |
| US-5731348-A | NERVOUS SYSTEM DISORDERS | BEARSDEN BIO, INC. (US) | 1998-03-24 | — | — | US | claimed |
| EP-0809624-A1 | ALKYLCARBOXY AMINO ACIDS-MODULATORS OF THE KAINATE RECEPTOR | Bearsden Bio, Inc. (US) | 1997-12-03 | — | — | EP | claimed |
| WO-1996025387-A1 | ALKYLCARBOXY AMINO ACIDS-MODULATORS OF THE KAINATE RECEPTOR | SYMPHONY PHARMACEUTICALS, INC. (US) | 1996-08-22 | — | — | WO | claimed |
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| US-20240342136-A1 | Glutamate receptor agonists for suppression of mast cell function | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-10-17 | — | — | US | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| EP-1314041-A2 | SCREEN FOR GLUTAMATE REUPTAKE INHIBITORS, STIMULATORS, AND MODULATORS | Annovis, Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020115688-A1 | Screen for glutamate reuptake inhibitors, stimulators, and modulators | ANNOVIS, INC. | 2002-08-22 | — | — | US | disclosed |
| WO-2002018941-A2 | SCREEN FOR GLUTAMATE REUPTAKE INHIBITORS, STIMULATORS, AND MODULATORS | ANNOVIS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115688-A1 | Screen for glutamate reuptake inhibitors, stimulators, and modulators | SLC18A2, SLC1A2, SLC1A1 | SLC7A5 56/4885SLC1A3 5/4885SLC1A2 2/4885 |
| US-20240342136-A1 | Glutamate receptor agonists for suppression of mast cell function | GRM6, GPR17, GRM3 | SLC7A5 878/4885SLC1A3 60/4885SLC1A2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.